Ultragenyx Pharmaceutical Inc. (RARE) 69.65 $RARE
Ultragenyx Announces Positive Data from Triheptanoin Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 3:36PM CDT
Ultragenyx (RARE) announced positive data from an investigator-sponsored study on triheptanoin for glucose transporter type-1 deficiency syndrome.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), RARE: 69.65 (+0.75), AVEO: 1.92 (-0.08)
Ultragenyx's triheptanoin receives two new Orphan Drug designations
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 10:30AM CDT
RARE: 69.65 (+0.75)
Ultragenyx Granted Additional Orphan Drug Designations for Triheptanoin
GlobeNewswire - Thu Apr 23, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has received two orphan drug designations for triheptanoin (UX007). The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation for triheptanoin for the treatment of fatty acid oxidation disorders (FAOD), and the European Commission has granted orphan medicinal product designation for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS). The FDA granted orphan drug designation for triheptanoin in Glut1 DS in October 2014.
RARE: 69.65 (+0.75)
Ultragenyx Announces Positive Data From Investigator-Sponsored Trial of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome
GlobeNewswire - Wed Apr 22, 6:30AM CDT
Data Demonstrate a Substantial Reduction in Movement Disorder Events
RARE: 69.65 (+0.75)
Ultragenyx Appoints Daniel G. Welch to Board of Directors
GlobeNewswire - Mon Apr 13, 8:08AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Daniel G. Welch to the company's Board of Directors effective April 8, 2015. Mr. Welch, former Chairman and Chief Executive Officer of InterMune and current Executive Partner at Sofinnova Ventures, will serve as an independent director to Ultragenyx.
RARE: 69.65 (+0.75)
Ultragenyx Pharmaceutical (RARE): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:41AM CDT
Ultragenyx Pharmaceutical is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
RARE: 69.65 (+0.75)
Ultragenyx Pharma net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 5:37AM CDT
RARE: 69.65 (+0.75)
Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Discusses Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 25, 10:54PM CDT
RARE: 69.65 (+0.75)
Ultragenyx Pharmaceutical beats by $0.01
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 3:35PM CDT
RARE: 69.65 (+0.75)
Ultragenyx reports 4Q loss
Automated Insights - Wed Mar 25, 3:33PM CDT
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Wednesday reported a loss of $16.7 million in its fourth quarter.
RARE: 69.65 (+0.75)
Ultragenyx Reports Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update
GlobeNewswire - Wed Mar 25, 3:05PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the fourth quarter and full-year ended December 31, 2014.
RARE: 69.65 (+0.75)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update
GlobeNewswire - Fri Mar 20, 6:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Wednesday, March 25, 2015 at 5pm ET to discuss fourth quarter and full-year 2014 financial results and provide a corporate update.
RARE: 69.65 (+0.75)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.52 (-0.03), MDT: 77.61 (-0.89), RARE: 69.65 (+0.75), PFE: 35.27 (-0.09), SUPN: 13.76 (-0.18), NRX: 8.26 (-0.08), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), SVA: 5.10 (unch), BLRX: 2.10 (-0.02), AMPH: 15.25 (-0.04), CHRS: 23.52 (-0.88), JNJ: 101.08 (+0.62), GNVC: 2.82 (+0.01), CYCC: 0.96 (+0.02), AZN: 71.79 (-1.34), DPRX: 12.85 (+0.27), TEVA: 64.41 (+1.16), NBY: 0.63 (unch)
Ultragenyx Announces Presentation of Disease Burden Data in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Mar 09, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of data highlighting the significant impairment in skeletal health outcomes and physical function in adult patients affected by X-linked hypophosphatemia (XLH). The data were presented at the 2015 ENDO meeting of The Endocrine Society in San Diego, California. The data were generated from a 13-country disease burden survey, conducted by Ultragenyx, which was completed to further characterize the significant health challenges facing this patient population. XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness. A total of 165 adults with XLH from 13 countries elected to complete an institutional review board approved online questionnaire to assess medical and diagnostic history.
RARE: 69.65 (+0.75)
Ultragenyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Feb 17, 8:50AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the underwriters of the previously announced offering of 3,000,000 shares of common stock have exercised in full their option to purchase an additional 450,000 shares from the company at the public offering price of $54.00 per share, before underwriting discounts. The closing of the option exercise is expected to occur on February 19, 2015, subject to customary closing conditions.
RARE: 69.65 (+0.75)
Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Tue Feb 10, 3:30PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive 36-week data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented in poster and oral presentations by Dr. Emil Kakkis, Chief Executive Officer of Ultragenyx, at the 11Annual WORLD Symposium in Orlando, Florida.
RARE: 69.65 (+0.75)
Ultragenyx prices public offering at USD54.00 per share
M2 - Fri Feb 06, 4:21AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) said on Thursday that it has priced a public offering of 3,000,000 common stock shares.
RARE: 69.65 (+0.75)
Ultragenyx prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:11AM CST
RARE: 69.65 (+0.75)
Ultragenyx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 6:09PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $54.00 per share, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 450,000 shares of the company's common stock at the public offering price, less the underwriting discount.
RARE: 69.65 (+0.75)
Ultragenyx to issue up to USD125m of common stock in public offering
M2 - Wed Feb 04, 5:24AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) Tuesday reported the start of its planned public offering of up to USD125m of shares of its common stock.
RARE: 69.65 (+0.75)
Ultragenyx Announces Positive Data from Triheptanoin Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 3:36PM CDT
Ultragenyx (RARE) announced positive data from an investigator-sponsored study on triheptanoin for glucose transporter type-1 deficiency syndrome.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), RARE: 69.65 (+0.75), AVEO: 1.92 (-0.08)
Ultragenyx's triheptanoin receives two new Orphan Drug designations
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 10:30AM CDT
RARE: 69.65 (+0.75)
Ultragenyx Granted Additional Orphan Drug Designations for Triheptanoin
GlobeNewswire - Thu Apr 23, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has received two orphan drug designations for triheptanoin (UX007). The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation for triheptanoin for the treatment of fatty acid oxidation disorders (FAOD), and the European Commission has granted orphan medicinal product designation for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS). The FDA granted orphan drug designation for triheptanoin in Glut1 DS in October 2014.
RARE: 69.65 (+0.75)
Ultragenyx Announces Positive Data From Investigator-Sponsored Trial of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome
GlobeNewswire - Wed Apr 22, 6:30AM CDT
Data Demonstrate a Substantial Reduction in Movement Disorder Events
RARE: 69.65 (+0.75)
Ultragenyx Appoints Daniel G. Welch to Board of Directors
GlobeNewswire - Mon Apr 13, 8:08AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Daniel G. Welch to the company's Board of Directors effective April 8, 2015. Mr. Welch, former Chairman and Chief Executive Officer of InterMune and current Executive Partner at Sofinnova Ventures, will serve as an independent director to Ultragenyx.
RARE: 69.65 (+0.75)
Ultragenyx Pharmaceutical (RARE): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:41AM CDT
Ultragenyx Pharmaceutical is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
RARE: 69.65 (+0.75)
Ultragenyx Pharma net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 5:37AM CDT
RARE: 69.65 (+0.75)
Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Discusses Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 25, 10:54PM CDT
RARE: 69.65 (+0.75)
Ultragenyx Pharmaceutical beats by $0.01
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 3:35PM CDT
RARE: 69.65 (+0.75)
Ultragenyx reports 4Q loss
Automated Insights - Wed Mar 25, 3:33PM CDT
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Wednesday reported a loss of $16.7 million in its fourth quarter.
RARE: 69.65 (+0.75)
Ultragenyx Reports Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update
GlobeNewswire - Wed Mar 25, 3:05PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the fourth quarter and full-year ended December 31, 2014.
RARE: 69.65 (+0.75)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update
GlobeNewswire - Fri Mar 20, 6:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Wednesday, March 25, 2015 at 5pm ET to discuss fourth quarter and full-year 2014 financial results and provide a corporate update.
RARE: 69.65 (+0.75)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.52 (-0.03), MDT: 77.61 (-0.89), RARE: 69.65 (+0.75), PFE: 35.27 (-0.09), SUPN: 13.76 (-0.18), NRX: 8.26 (-0.08), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), SVA: 5.10 (unch), BLRX: 2.10 (-0.02), AMPH: 15.25 (-0.04), CHRS: 23.52 (-0.88), JNJ: 101.08 (+0.62), GNVC: 2.82 (+0.01), CYCC: 0.96 (+0.02), AZN: 71.79 (-1.34), DPRX: 12.85 (+0.27), TEVA: 64.41 (+1.16), NBY: 0.63 (unch)
Ultragenyx Announces Presentation of Disease Burden Data in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Mar 09, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of data highlighting the significant impairment in skeletal health outcomes and physical function in adult patients affected by X-linked hypophosphatemia (XLH). The data were presented at the 2015 ENDO meeting of The Endocrine Society in San Diego, California. The data were generated from a 13-country disease burden survey, conducted by Ultragenyx, which was completed to further characterize the significant health challenges facing this patient population. XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness. A total of 165 adults with XLH from 13 countries elected to complete an institutional review board approved online questionnaire to assess medical and diagnostic history.
RARE: 69.65 (+0.75)
Ultragenyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Feb 17, 8:50AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the underwriters of the previously announced offering of 3,000,000 shares of common stock have exercised in full their option to purchase an additional 450,000 shares from the company at the public offering price of $54.00 per share, before underwriting discounts. The closing of the option exercise is expected to occur on February 19, 2015, subject to customary closing conditions.
RARE: 69.65 (+0.75)
Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Tue Feb 10, 3:30PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive 36-week data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented in poster and oral presentations by Dr. Emil Kakkis, Chief Executive Officer of Ultragenyx, at the 11Annual WORLD Symposium in Orlando, Florida.
RARE: 69.65 (+0.75)
Ultragenyx prices public offering at USD54.00 per share
M2 - Fri Feb 06, 4:21AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) said on Thursday that it has priced a public offering of 3,000,000 common stock shares.
RARE: 69.65 (+0.75)
Ultragenyx prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:11AM CST
RARE: 69.65 (+0.75)
Ultragenyx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 6:09PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $54.00 per share, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 450,000 shares of the company's common stock at the public offering price, less the underwriting discount.
RARE: 69.65 (+0.75)
Ultragenyx to issue up to USD125m of common stock in public offering
M2 - Wed Feb 04, 5:24AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) Tuesday reported the start of its planned public offering of up to USD125m of shares of its common stock.
RARE: 69.65 (+0.75)
